JP7700093B2 - 多反応性が低下した抗ｈｉｖワクチン抗体 - Google Patents

多反応性が低下した抗ｈｉｖワクチン抗体 Download PDF

Info

Publication number
JP7700093B2
JP7700093B2 JP2022500950A JP2022500950A JP7700093B2 JP 7700093 B2 JP7700093 B2 JP 7700093B2 JP 2022500950 A JP2022500950 A JP 2022500950A JP 2022500950 A JP2022500950 A JP 2022500950A JP 7700093 B2 JP7700093 B2 JP 7700093B2
Authority
JP
Japan
Prior art keywords
receptor
killer cell
antigen
antibody
substitution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022500950A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022539877A (ja
Inventor
シヴァーズ，スチュアート，エー．
キーフ，ジェニファー
ヌッセンツワィグ，ミシェル，シー．
ビョルクマン，パメラ，ジェイ．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University filed Critical Rockefeller University
Publication of JP2022539877A publication Critical patent/JP2022539877A/ja
Priority to JP2024177043A priority Critical patent/JP2025011201A/ja
Application granted granted Critical
Publication of JP7700093B2 publication Critical patent/JP7700093B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
JP2022500950A 2019-07-08 2020-07-08 多反応性が低下した抗ｈｉｖワクチン抗体 Active JP7700093B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024177043A JP2025011201A (ja) 2019-07-08 2024-10-09 多反応性が低下した抗ｈｉｖワクチン抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962871393P 2019-07-08 2019-07-08
US62/871,393 2019-07-08
PCT/US2020/041138 WO2021007285A1 (en) 2019-07-08 2020-07-08 Anti-hiv vaccine antibodies with reduced polyreactivity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024177043A Division JP2025011201A (ja) 2019-07-08 2024-10-09 多反応性が低下した抗ｈｉｖワクチン抗体

Publications (2)

Publication Number Publication Date
JP2022539877A JP2022539877A (ja) 2022-09-13
JP7700093B2 true JP7700093B2 (ja) 2025-06-30

Family

ID=74114255

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022500950A Active JP7700093B2 (ja) 2019-07-08 2020-07-08 多反応性が低下した抗ｈｉｖワクチン抗体
JP2024177043A Pending JP2025011201A (ja) 2019-07-08 2024-10-09 多反応性が低下した抗ｈｉｖワクチン抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024177043A Pending JP2025011201A (ja) 2019-07-08 2024-10-09 多反応性が低下した抗ｈｉｖワクチン抗体

Country Status (9)

Country Link
US (1) US12459990B2 (enExample)
EP (1) EP3997119A4 (enExample)
JP (2) JP7700093B2 (enExample)
KR (1) KR20220047977A (enExample)
CN (1) CN114641488A (enExample)
AU (1) AU2020311902A1 (enExample)
CA (1) CA3146372A1 (enExample)
TW (1) TW202116800A (enExample)
WO (1) WO2021007285A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024097957A1 (en) * 2022-11-03 2024-05-10 Duke University Novel antibodies for hiv and methods of making and using the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013090644A2 (en) 2011-12-13 2013-06-20 California Institute Of Technology Anti-hiv antibodies having increased potency and breadth
WO2018183294A1 (en) 2017-03-27 2018-10-04 David Weiner Dna antibody constructs for use against hiv

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014205491A1 (en) 2013-06-25 2014-12-31 Monash University Biological molecules and methods of use
US20180028658A1 (en) 2015-02-16 2018-02-01 New York Blood Center, Inc. Antibody-drug conjugates for reducing the latent hiv reservoir
US10450368B2 (en) * 2015-03-19 2019-10-22 Duke University HIV-1 neutralizing antibodies and uses thereof (CD4bs antibodies)
CA2983034A1 (en) * 2015-04-17 2016-10-20 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
EA201891186A1 (ru) * 2015-12-15 2018-12-28 Джилид Сайэнс, Инк. Антитела, нейтрализующие вирус иммунодефицита человека
PE20210685A1 (es) * 2018-07-03 2021-04-08 Gilead Sciences Inc Anticuerpos que se dirigen al gp120 de vih y metodos de uso

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013090644A2 (en) 2011-12-13 2013-06-20 California Institute Of Technology Anti-hiv antibodies having increased potency and breadth
WO2018183294A1 (en) 2017-03-27 2018-10-04 David Weiner Dna antibody constructs for use against hiv

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Immunity，2016年，Vol. 45, No. 5，pp. 1108-1121

Also Published As

Publication number Publication date
CA3146372A1 (en) 2021-01-14
KR20220047977A (ko) 2022-04-19
WO2021007285A1 (en) 2021-01-14
EP3997119A4 (en) 2023-11-22
US20220289829A1 (en) 2022-09-15
US12459990B2 (en) 2025-11-04
JP2025011201A (ja) 2025-01-23
EP3997119A1 (en) 2022-05-18
TW202116800A (zh) 2021-05-01
JP2022539877A (ja) 2022-09-13
CN114641488A (zh) 2022-06-17
AU2020311902A1 (en) 2022-01-27

Similar Documents

Publication Publication Date Title
JP7455156B2 (ja) ＨＩＶ ｇｐ１２０を標的化する抗体および使用方法
US12195524B2 (en) Multi-specific antigen binding molecules targeting HIV and methods of use
JP2025011201A (ja) 多反応性が低下した抗ｈｉｖワクチン抗体
KR20230107288A (ko) gp120 CD4 결합 부위-지향 항체를 이용한 요법에 감수성인 HIV 환자를 식별하는 방법
HK40067703A (en) Anti-hiv vaccine antibodies with reduced polyreactivity
HK40098397A (en) Antibodies that target hiv gp120 and methods of use
EA048133B1 (ru) АНТИТЕЛА, КОТОРЫЕ НАЦЕЛЕНЫ НА ГЛИКОПРОТЕИН gp120 ВИРУСА ИММУНОДЕФИЦИТА ЧЕЛОВЕКА (ВИЧ), И СПОСОБЫ ИХ ПРИМЕНЕНИЯ

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230707

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241009

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250220

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250520

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250618

R150 Certificate of patent or registration of utility model

Ref document number: 7700093

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150